Clinical

The drug significantly delayed recurrence of the cancer in patients treated post surgery.

What we're reading, October 28, 2015: Ben Carson plans to replace the Affordable Care Act, Medicaid, and Medicare; a homeless shelter utilizes telemedicine to alleviate emergency department visits; and researchers uncover gender gap in post-heart attack treatment.

Payer—provider teams presented updates on their cost-saving pilot projects and looked to the future of these models in oncology care.

Twenty-four states have received grants to improve the behavioral health of their citizens by providing community-based mental and substance use disorder treatment.

The company says the treatment will cost an average of $65,000.

The ASCO statement emphasizes patient-centered reform that weighs-in the value of the services rendered.

What we're reading, October 27, 2015: a much-improved Healthcare.gov website, report says drug prices rose at a much slower rate in 2015, and USPSTF recommends glucose testing in asymptomatic adults who are overweight or obese.

The vaccine, approved in Europe last week, is now awaiting approval in the United States.

Despite the fact that post-bronchodilator spirometry is required for the diagnosis of chronic obstructive pulmonary disease, an analysis of primary care clinics found only 19% of patients diagnosed with the disease had undergone spirometry testing.

Three important patient-reported outcomes can help predict hospitalizations among patients with chronic obstructive pulmonary disease, potentially helping clinicians to categorize patients' level of risk and design preventive interventions and proper care.

A study published in the journal Cancer presents the financial impact of cancer on a survivor and his family.

Two head-to-head trials comparing the safety of Incruse Ellipta to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease has yielded positive results for GlaxoSmithKline's therapy.

The drug is awaiting an FDA verdict next week.

As the date for the comment period on the proposed guidance by HHS on 340B drug pricing draws near, read about the program and its impact on healthcare overall.

Published in JAMA Oncology, the study found a significant difference in quality and access to care for black patients diagnosed with localized prostate cancer.